About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: PACB
- CUSIP: 69404D10
- Previous Close: $5.12
- 50 Day Moving Average: $4.90
- 200 Day Moving Average: $7.01
- 52-Week Range: $92,677,000.00 - $3.76
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.00
- P/E Growth: -0.19
- Market Cap: $474.51M
- Outstanding Shares: 92,677,000
- Beta: 1.97
- Net Margins: -81.99%
- Return on Equity: -75.50%
- Return on Assets: -49.35%
Companies Related to Pacific Biosciences of California:
- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 3.82%
- Quick Ratio: 3.30%
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2017?
5 brokerages have issued 1-year price targets for Pacific Biosciences of California's stock. Their predictions range from $8.00 to $16.50. On average, they expect Pacific Biosciences of California's share price to reach $11.70 in the next year.
When will Pacific Biosciences of California announce their earnings?
Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Wednesday, April, 19th 2017.
What are analysts saying about Pacific Biosciences of California stock?
Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)
According to Zacks Investment Research, "In the past six months, Pacific Biosciences’ share price persistently underperformed the broader industry trend. However, in the last 30 days, earnings estimates have been moved downwards reflecting sluggish third quarter performance. We note that, Pacific Biosciences exhibited a promising third quarter of 2016, registering narrower loss on a year-over-year basis and squarely beating the Zacks Consensus Estimate. However, the guidance cut for the full year fails to impress. Solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. On the flipside, persistent losses and cash burn are the primary headwinds. Moreover, the headwind related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system, flat contractual revenues in the last reported quarter and higher non-cash operating expenses will hurt the" (11/29/2016)
Who owns Pacific Biosciences of California stock?
Pacific Biosciences of California's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Arrowpoint Asset Management LLC (1.59%), State Street Corp (1.50%), Levin Capital Strategies L.P. (1.13%), Alyeska Investment Group L.P. (0.53%), Allianz Asset Management AG (0.45%) and Thrax Management LLC (0.44%). Company insiders that own Pacific Biosciences of California stock include Brian B Dow, James Michael Phillips and Kevin P Corcoran.
Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?
Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, AQR Capital Management LLC and Commerzbank Aktiengesellschaft FI.
Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?
Pacific Biosciences of California's stock was purchased by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Arrowpoint Asset Management LLC, Alyeska Investment Group L.P., Russell Investments Group Ltd., Tudor Investment Corp Et Al, State Street Corp, Moloney Securities Asset Management LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought Pacific Biosciences of California stock in the last two years include Brian B Dow and Kevin P Corcoran.
How do I buy Pacific Biosciences of California stock?
Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pacific Biosciences of California stock cost?
One share of Pacific Biosciences of California stock can currently be purchased for approximately $5.12.